Insider Selling: Sangamo Biosciences CFO Unloads 10,000 Shares of Stock (SGMO)
Sangamo Biosciences (NASDAQ:SGMO) CFO Henry Ward Wolff unloaded 10,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $14.17, for a total value of $141,700.00. Following the transaction, the chief financial officer now directly owns 218,347 shares in the company, valued at approximately $3,093,977. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of Sangamo Biosciences in a research note on Friday, August 1st. They set an “overweight” rating and a $22.00 price target on the stock.
Shares of Sangamo Biosciences (NASDAQ:SGMO) traded down 2.96% on Tuesday, hitting $13.76. 554,468 shares of the company’s stock traded hands. Sangamo Biosciences has a 1-year low of $8.93 and a 1-year high of $24.69. The stock has a 50-day moving average of $13.6 and a 200-day moving average of $15.96. The company’s market cap is $937.9 million.
Sangamo Biosciences (NASDAQ:SGMO) last released its earnings data on Wednesday, July 23rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.04. The company had revenue of $10.38 million for the quarter, compared to the consensus estimate of $7.84 million. During the same quarter in the previous year, the company posted ($0.10) earnings per share. The company’s revenue for the quarter was up 50.4% on a year-over-year basis. Analysts expect that Sangamo Biosciences will post $-0.26 EPS for the current fiscal year.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.